Patients who have developed chronic myeloid leukemia may be prescribed a number of different treatment options, some of which could lead to significant side effects.

If not captured quickly, chronic myeloid leukemia may become very dangerous for patients. For some patients who have developed this condition or lost their loved ones because of it, troubling research about drug risks is raising the stakes for whether or not lawsuits will be soon to follow these claims.

Concerns over Tasigna atherosclerosis have emerged in recent years by patients who claim that they developed cardiovascular problems after taking the medication to manage their chronic myeloid leukemia. Tasigna was originally approved by the FDA in 2007 as a treatment option for chronic myeloid leukemia. Over twelve studies conducted all over the globe have raised issues regarding Tasigna atherosclerosis.

The potentially life-threatening risk of atherosclerosis may be associated with the hardening, narrowing or clogging of a patient’s arteries. Tasigna is a popular cancer drug, but more patients have reported issues with circulatory or cardiovascular issues after taking the medication and claim that the manufacturer never adequately warned them or their doctors about the problems.

Dangers of Tasigna Reported by Patients and New Studies

According to the FDA, treatment with Tasigna may lead to swelling in the patient’s arteries, which can ultimately lead to restricted blood flow affecting the heart, arms, brain, legs, or any other portion of the body. Ultimately, this could lead to amputation of the limbs or death, in addition to the cardiovascular problems reported by many different patients.

A number of different serious side effects beyond Tasigna atherosclerosis could be associated with the medication, including amputation, heart attack, embolic occlusion, coronary artery disease, peripheral arterial disease, circulatory issues, infection or even death.

Unfortunately, as many patients began to receive the medication, they came forward with concerns about Tasigna atherosclerosis. Atherosclerosis can lead to hardened and thickened artery walls, which puts blood flow at risk due to the buildup of plaque inside the artery walls.

When plaque buildup becomes inflamed or brittle, it can trigger a blood clot to form and the blood clot can prove fatal for the patient. Tasigna was approved with a black box warning that was associated with other side effects related to the drug. However, the risk of Tasigna atherosclerosis was not added to the label until several years later.

Medical journals published throughout Canada, Europe, and the United States raised issues regarding Tasigna atherosclerosis. The first connection was found in 2011, in a study reporting that one-quarter of patients experienced vascular problems after receiving a prescription for the drug. Approximately 16 percent of patients in that study suffered from peripheral arterial disease due to taking the drug.

In 2013, nine additional Tasigna atherosclerosis studies were published, including an FDA post-market review that explored the number of adverse event reports filed directly with the agency. Those patients who may have developed Tasigna atherosclerosis and were never properly warned about the dangers of the drug may have grounds to participate in a class action lawsuit.